Pear Therapeutics Obtains FDA Authorization for SOMRYST™

Pear Therapeutics, Inc. today announced the U.S. Food and Drug Administration (FDA) has granted authorization for Somryst™, the first prescription digital therapeutic (PDT) intended for use in the treatment of patients 22 years of age and older with chronic insomnia.